Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
Will tell you your local walk in centre.
RW, sincere condolences.
Kx
Just so utterly negative,
A point in time , projecting this situation to be a blot on Scancells copybook.
Do you really know the bigger picture AB?
To AB,
Help out when i can,
Really do not think if its politically correct or not.
Atb Kat
Ray ... the targets in SCIB2 are based around the HLA not future epitope variants
this allows immunobody to be more universal
Lets hope that it takes nothing away from Scancell,s vast and potentially valuable portfolio.
As many of us have been here for years and do not want to see our potential gains filtered into another new IPO
fragma22 Jun '21 - 23:29 - 40464 of 40464
0 0 0
From what we have heard, itβs been created for a potential spin out IPO next month
For which trial?
Wonderful editorial in The Guardian this am regarding the lack of state healthcare,and the politics alongside.
A government for the rich and telling the sick and covid affected not to behave like babies.
Thank you for you take on events.
After about 9 years another month makes little difference.
If their position is as good as expected, they have no need to hurry as all their prep work will be done and ready to go.
Article was out on 10 March...
What are you seeing?
Your Highlights
avatar
Jonathan Ball
@JonathanKBall
RT @PostdocPat: A preprint with examples of our @UoNLifeSci & @CovidGenomicsUK SARS-CoV-2 whole genome sequencing work in Nottingham with Nβ¦
Cleanerworld,
Crumbs posts,
All of his excellent posts are available in his history.
interesting paper:
https://www.biorxiv.org/content/10.1101/2021.03.20.436257v1.full.pdf+html
This caught my eye:
'In addition to Spike, emerging variants exhibited mutations in nucleocapsid, 152 membrane and nonstructural proteins NSP3, NSP6 and NSP12 (Supplementary Table 1).'
o then its all down to .......... Target
1/ Immunobody has shown to invoke High Avidity
2/ Lindy has boosted that with Avidmab
3/ Have Scancell chosen the right targets .....
1 to 3 = what's the blood work doing ............
if we get 1/3 ... the ""how many you are holding really does come into play""
because you are not just valuing "Covidity" ........... you are Valuing possibly the most potent vaccine against any virus
Oxford Scientist on the BBC after the results of the US trial ........ are still looking at Antibodies ... on future variants they are still in the research phase
but remember Antibodies do not kill virus infected cells .......... that requires a cell mediated response CD8 and CD4
and the Most potent is "High Avidity"
What i have shown from recent posts is .........
If you want a vaccine to work Fast ....... High Avidity
If you want a broader response ........... High Avidity
If you want a strong memory T cell generated ....... High Avidity
Moreover, with wider variant cross-recognition capacity, broader T cell responses and stronger functionality profiles, high functional avidity CD8+ T cells also triggered effector functions more readily and undergo promptly expansion in vivo, help shaping their immunodominance4,7,8,9,10,11, leading to an efficient viral infected cells clearance12,13,14 and tumor cells elimination15,16. As a result, the avidity of T cells has been regarded as a major determinant of T cell functionality, control of viral infection and tumour elimination4,7,17,18.
hTTps://www.nature.com/articles/srep41558
What,s interesting ......
Its NOT a prophylactic vaccine
ISA106 is an SLP immunotherapy designed to elicit a strong and specific T cell immune response against multiple SARS-CoV2 antigens, with the intention ""to clear an established infection."" This therapy provides a treatment option for high risk patients that test positive for SARS-CoV2 infection and aims to prevent severe disease.
ISA106 is in late-stage preclinical development
Ivy
----
Amplivant can be applied to any SLP technology vaccine so ISA covid vaccine can be boosted further with Amplivant and probably is.
The exact data
patients with Tumour present 4mg and 8mg dose
No patient received checkpoint blockade prior to vaccination as these
treatments had not been approved at the time of the SCIB1
trial. Four patients received ipilimumab post-vaccination and
following disease progression. Three of these patients have died
and one is still alive.
on the adjuvant arm
No patients received
checkpoint blockade prior to vaccination as they had not been
approved at the time of the trial. One patient received ipilimumab and one received nivolumab post-vaccination and both
are still alive.
so 5 patients received Yervoy (ipilimumab) ctl-4
and one received Optivo (nivolumab) PD-1
no off target by SCIB1 reported and that would be an "AE" event as it would be serious
""In this
trial, no patients received checkpoint inhibitors prior to vaccination but six patients (four with tumor and two with no tumor
at study entry) received ipilimumab or nivolumab post-vaccination and three of these patients are still alive. Although these
patient numbers are low, this suggests that SCIB1 vaccination
may prime for responses to checkpoint inhibition.""
a further indication that Scancell SCIB1 trial may prove very effective with the checkpoints
Burble
You posted
"""Interesting to note that on top of failing to meet the primary end point it showed more adverse effects in the combo arm than in the control arm.
We should therefore take this on board for our own combo trial. Always a risk! But onwards and upwards.""""
"""Our lead investigational agent, tilsotolimod, activates TLR9. In cancer patients with solid tumors, tilsotolimod is injected directly into a tumor to trigger TLR9 into action and prime a local immune response to help attack the tumor. This has been demonstrated in pre-clinical models, and our translational studies during early clinical trials have shown rapid immune activation in the injected tumor along with systemic increases in T cells.
Idera is investigating the combination of tilsotolimod with checkpoint inhibitors and other immune activators with the aim of providing improved outcomes for patients in need.""
How can you compare an injected in tumor adjuvant with Immunobody
and even consider that the Immunobody would carry the same sort of Risk profile specifically because it has been in trial and not displayed any toxicity apart from, like all vaccines sore arm etc. Not only that its using Yervoy probably the most toxic of all the check points compared with keytruda
I would remind you that Keytruda locks onto T cells ........ its systemic because it locks on to all t Cells
Scancells immunobody does not even need adjuvants to generate potent t cells
so its impossible to compare with tilsotolimod